An animal model of pain produced by systemic administration of an immunotherapeutic anti-ganglioside antibody

Pain

Volumn 69, Issue 1-2, 1997, Pages 119-125

  Slart, R ^a   Yu, A L ^b   Yaksh, T L ^c   Sorkin, L S ^c,d  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c University of California at San Diego   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Allodynia; GD2 ganglioside; Monoclonal antibody

Indexed keywords

GANGLIOSIDE GD2; MONOCLONAL ANTIBODY;

ALLODYNIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; MALE; NOCICEPTION; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIBODIES, MONOCLONAL; BEHAVIOR, ANIMAL; GANGLIOSIDES; HEMODYNAMIC PROCESSES; HUMANS; HYPERALGESIA; IMMUNOTHERAPY; INJECTIONS, INTRAVENOUS; MALE; MICE; PAIN; PAIN THRESHOLD; PHYSICAL STIMULATION; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0031049821     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3959(96)03247-2     Document Type: Article

References (29)

1. Arai, M., Yoshino, H., Kusano, Y., Yazaki, Y., Ohnishi, Y. and Miyatake, T., Ataxic polyneuropathy and anti-Pr2 IgM proteinemia, J. Neurol., 239 (1992) 147-151.
2. Barker, E., Mueller, B.M., Handgretinger, R., Herter, M., Yu, A.L. and Reisfeld, R.A., Effect of a chimeric anti-ganglioside GD2 antibody on cell-mediated lysis of human neuroblastoma cells, Cancer Res., 51 (1991) 144-149.
3. Breslow, N. and McCann, B., Statistical estimation of prognosis for children with neuroblastoma, Can. Res., 341 (1971) 2098-2103.
4. Chaplan, S.R., Bach, F.W., Pogrel, J.W., Chung, J.M. and Yaksh, T.L., Quantitative assessment of tactile allodynia in the rat paw, J. Neurosci. Meth., 53 (1994) 55-63.
5. Cheung, N.K., Landmeier, B., Neely, J., Nelson, A.D., Abramawsky, C., Ellery, S., Adams, R.B. and Miraldy, F., Complete tumor ablation with iodine 131-radiolabeled disialoganglioside GD2-specific monoclonal antibody against human neuroblastoma xenografted in nude mice, J. Natl. Can. Instil., 77 (1986) 739-745.
6. Cheung, N.K.V., Lazarus, H., Miraldi, F.D., Abramowsky, C.R., Kallick, S., Saarinen, U.M., Spitzer, T., Strandjord, S.E., Coccia, P.F. and Berger, N.A., Ganglioside GD2 specific monoclonal antibody 3F8: A phase I study in patients with neuroblastoma and malignant melanoma, J. Clin. Oncol., 5 (1987) 1430-1440.
7. Daune, G.C., Farrer, R.G., Dalakas, M.C. and Quarles, R.H., Sensory neuropathy associated with monoclonal immunoglobulin M to GD1b ganglioside, Ann. Neural., 31 (1992) 683-685.
8. Dixon, W.J., Efficient analysis of experimental observations, Ann. Rev. Pharmacol. Toxicol., 20 (1980) 441-462.
9. Favaron, M., Manev, H., Alho, H., Bertolino, M., Ferrret, B., Guidotti, A. and Costa, E., Gangliosides prevent glutamate and kainate neurotoxicity in primary neuronal cultures of neonatal rat cerebellum and cortex, Proc. Natl. Acad. Sci. USA, 85 (1988) 7351-7355.
10. Fromm, C., DeLeo, J.A., Coombs, D.W. and Twitchell, B.B., The ganglioside GM1 decreases autotomy but not substance P depletion in a peripheral mononeuropathy model, Anesth. Analg., 77 (1993) 501-506.
11. Gillies, S.D., Lo, K.M. and Wesolowski, J., High level expression of chimeric antibodies using adapted cDNA variable region cassettes, J. Immunol. Meth., 125 (1989) 191-202.
12. Handgretinger, R., Baader, P., Dopfer, R., Klingbiel, T., Reuland, P., Treuner, J., Reisfeld, R.A. and Niethammer, D., A phase I study of neuroblastoma with the anti-ganglioside GD2 antibody 14G2a, Cancer Immunol. Immunother., 35 (1992) 199-204.
13. Hayes, R.L., Mao, J., Price, D.D., Germano, A., d'Avella, D., Fiori, M. and Mayer, D.J., Pretreatment with gangliosides reduces abnormal nociceptive responses associated with a rodent peripheral neuropathy, Pain, 48 (1992) 391-396.
14. Huang, C.S., Uttenreuther, M., Reisfeld, R.A. and Yu, A.L., Immunotherapy of GD2(+) tumors with a murine monoclonal antibody (MAB) 14G2a: A phase I study, Proc. ASCO, 11 (1992) 21.
15. Ilyas, A.A., Quarles, R.H., Dalakas, M.C., Fishman, P.M. and Brady, R.O., Monoclonal IgM in a patient with paraproteinemic polyneuropathy binds to gangliosides containing disialosyl groups, Ann. Neurol., 18 (1985) 655-659.
16. Kracun, I., Rösner, H. and Cosovic, C., Topographical distribution of the gangliosides in the developing and adult human brain. In: G. Tettamanti, R.W. Ledeen, K. Sandkoff, Y. Nagai, and G. Toffano (Eds.), Gangliosides And Neuronal Plasticity, Fidia Research Series, Vol. 6, Liviana, Padova, pp. 67-76.
17. Malmberg, A.B., Yaksh, T.L. and Calcutt, N.A., Anti-nociceptive effects of the GM1 ganglioside derivative AGF 44 on the formalin test in normal and streptozotocin-diabetic rats, Neurosci. Lett., 161 (1993) 45-48.
18. Obi, T., Kusunoki, S., Takatsu, M., Mizoguchi, K., and Nishimura, Y., IgM M-protein in a patient with sensory-dominant neuropathy binds preferentially to polysialogangliosides, Acta. Neurol. Scand., 86 (1992) 215-218.
19. Ohsawa, T., Miyatake, T. and Yuki, N., Anti-B-series ganglioside-recognizing autoantibodies in an acute sensory neuropathy patient cause cell death of rat dorsal root ganglion neurons, Neurosci. Lett., 157 (1993) 167-170.
20. Rosen, E.M., Cassady, J.R., Frantz, C.N., Kretschmar, C., Levey, R. and Sallin, S.E., Neuroblastoma: the Joint Center for Radiation Therapy/ Dana-Farber Cancer Institute/Children's Hospital experience, J. Clin Oncol., 2 (1985) 719-732.
21. Saleh, M.N., Khazeli, M.B., Wheeler, R., Dropcho, E., Liu, T., Urist, M., Miller, D., Lawson, S., Dixon, P. and Russel, C., Phase I trial of the murine monoclonal anti-GD2 antibody 14G2a in metastatic melanoma, Cancer Res., 52 (1992) 4342-4347.
22. Schultz, G., Cheresh, D.A., Varki, N.M., Yu, A., Staffileno, L.K. and Reisfeld R.A., Detection of ganglioside GD2 in tumor tissues and sera neuroblastoma patients, Cancer Res., 44 (1984) 5914-5920.
23. Shafford, E.A., Rogers, D.W. and Pritchard, J., Advanced neuroblastoma: improved response rate using a multiagent regimen (OPEC) including sequential cisplatin and VM-26, J. Clin. Oncol., 31 (1984) 742-747.
24. Svennerholmn, L., Boström, K., Fredman, P., Jungbejer, B., Lekman, A., Månsson, J.-E. and Rynmark, B.-M., Gangliosides and allied glycosphingolipids in human peripheral nerve and spinal cord, Biochem. Biophys. Acta, 1214 (1994) 115-123.
25. Wargalla, U.C. and Reisfeld, R.A., Rate of internalization of an immunotoxin correlates with cytotoxic activity against human tumor cells, Proc. Natl. Acad. Sci. USA, 86 (1989) 5146-5150.
26. Yaksh, T.L., Harty, G.J. and Onofrio, B.M., High doses of spinal morphine produce a non-opiate receptor-mediated hyperesthesia: clinical and theoretical implications, Anesthesiology, 64 (1986) 590-597.
27. Young, J.L. Jr. and Miller, R.W., Incidence of malignant tumors in U.S. children, J. Ped., 86 (1975) 254-258.
28. Yu, A.L., Gillies, S.D. and Reisfeld, R.A., Phase I clinical trial of ch14.18 in patients with refractory neuroblastoma, Proc. ASCO, 10 (1991) 318.
29. Yu, A.L, Uttenreuther, M., Fischer, M.M., Huang, C.S., Reisfeld, R.A. and Fung, F.H., Phase I trial of patients with refractory neuroblastoma and osteosarcoma with human-mouse chimeric anti-disialoganglioside (GD2) monoclonal antibody ch14.18, J. Clin. Oncol. (1996) submitted.